268 related articles for article (PubMed ID: 28760299)
1. Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Sallman DA; Davila ML
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S26-S30. PubMed ID: 28760299
[TBL] [Abstract][Full Text] [Related]
2. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
Przespolewski AC; Griffiths EA
Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
5. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
6. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
7. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
Nagle SJ; Garfall AL; Stadtmauer EA
Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
[TBL] [Abstract][Full Text] [Related]
8. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
9. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
10. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.
Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ
Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565
[No Abstract] [Full Text] [Related]
11. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.
Guo Z; Tu S; Yu S; Wu L; Pan W; Chang N; Zhou X; Song C; Li Y; He Y
Cancer Sci; 2021 Apr; 112(4):1357-1368. PubMed ID: 33416209
[TBL] [Abstract][Full Text] [Related]
12. Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS).
Mann M; Brunner AM
Curr Probl Cancer; 2022 Feb; 46(1):100824. PubMed ID: 34980485
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches.
Noh JY; Seo H; Lee J; Jung H
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121189
[TBL] [Abstract][Full Text] [Related]
14. Introduction to a review series on emerging immunotherapies for hematologic diseases.
Paczesny S; Pavletic SZ; Bollard CM
Blood; 2018 Jun; 131(24):2617-2620. PubMed ID: 29728405
[TBL] [Abstract][Full Text] [Related]
15. T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.
Janelle V; Rulleau C; Del Testa S; Carli C; Delisle JS
Front Immunol; 2020; 11():276. PubMed ID: 32153583
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
17. Hematologic Malignancies: Plasma Cell Disorders.
Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
[TBL] [Abstract][Full Text] [Related]
18. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cell treatment in hematologic malignancies.
Goker H; Malkan UY; Demiroglu H; Buyukasik Y
Transfus Apher Sci; 2016 Feb; 54(1):35-40. PubMed ID: 26874466
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]